Rice Hall James & Associates LLC Takes $18.63 Million Position in QuidelOrtho Corporation $QDEL

Rice Hall James & Associates LLC acquired a new stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,063,559 shares of the company’s stock, valued at approximately $18,628,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Edgestream Partners L.P. acquired a new position in QuidelOrtho in the 1st quarter valued at about $1,937,000. Tejara Capital Ltd boosted its stake in shares of QuidelOrtho by 97.2% during the 4th quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock worth $5,950,000 after purchasing an additional 102,700 shares during the last quarter. Segall Bryant & Hamill LLC boosted its stake in shares of QuidelOrtho by 29.2% during the 1st quarter. Segall Bryant & Hamill LLC now owns 1,543,410 shares of the company’s stock worth $25,358,000 after purchasing an additional 348,549 shares during the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of QuidelOrtho by 84.1% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,525,900 shares of the company’s stock worth $25,071,000 after buying an additional 697,010 shares in the last quarter. Finally, Gagnon Securities LLC grew its holdings in shares of QuidelOrtho by 29.9% during the fourth quarter. Gagnon Securities LLC now owns 159,177 shares of the company’s stock worth $4,546,000 after buying an additional 36,678 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. UBS Group reaffirmed a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research note on Thursday, May 7th. JPMorgan Chase & Co. boosted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday, July 1st. Finally, Citigroup increased their price target on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, QuidelOrtho currently has a consensus rating of “Reduce” and an average target price of $13.62.

QuidelOrtho Stock Up 2.0%

QDEL opened at $14.58 on Tuesday. QuidelOrtho Corporation has a 12 month low of $9.92 and a 12 month high of $35.58. The business has a 50-day moving average of $15.80 and a two-hundred day moving average of $16.80. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The stock has a market capitalization of $999.75 million, a price-to-earnings ratio of -0.95 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same period in the prior year, the firm posted $0.12 EPS. The company’s revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, research analysts expect that QuidelOrtho Corporation will post 0.75 earnings per share for the current year.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.